Literature DB >> 21465257

Ataxia with oculomotor apraxia type1 (AOA1): novel and recurrent aprataxin mutations, coenzyme Q10 analyses, and clinical findings in Italian patients.

Barbara Castellotti1, Caterina Mariotti, Marco Rimoldi, Roberto Fancellu, Massimo Plumari, Sara Caimi, Graziella Uziel, Nardo Nardocci, Isabella Moroni, Giovanna Zorzi, Davide Pareyson, Daniela Di Bella, Stefano Di Donato, Franco Taroni, Cinzia Gellera.   

Abstract

Ataxia with oculomotor apraxia type1 (AOA1, MIM 208920) is a rare autosomal recessive disease caused by mutations in the APTX gene. We screened a cohort of 204 patients with cerebellar ataxia and 52 patients with early-onset isolated chorea. APTX gene mutations were found in 13 ataxic patients (6%). Eleven patients were homozygous for the known p.W279X, p.W279R, and p.P206L mutations. Three novel APTX mutations were identified: c.477delC (p.I159fsX171), c.C541T (p.Q181X), and c.C916T (p.R306X). Expression of mutated proteins in lymphocytes from these patients was greatly decreased. No mutations were identified in subjects with isolated chorea. Two heterozygous APTX sequence variants (p.L248M and p.D185E) were found in six families with ataxic phenotype. Analyses of coenzyme Q10 in muscle, fibroblasts, and plasma demonstrated normal levels of coenzyme in five of six mutated subjects. The clinical phenotype was homogeneous, irrespectively of the type and location of the APTX mutation, and it was mainly characterized by early-onset cerebellar signs, sensory neuropathy, cognitive decline, and oculomotor deficits. Three cases had slightly raised alpha-fetoprotein. Our survey describes one of the largest series of AOA1 patients and contributes in defining clinical, molecular, and biochemical characteristics of this rare hereditary neurological condition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21465257     DOI: 10.1007/s10048-011-0281-x

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  33 in total

1.  Type 1 ataxia with oculomotor apraxia with aprataxin gene mutations in two American children.

Authors:  Chang Y Tsao; George Paulson
Journal:  J Child Neurol       Date:  2005-07       Impact factor: 1.987

2.  Phenotypic variability of aprataxin gene mutations.

Authors:  C Tranchant; M Fleury; M C Moreira; M Koenig; J M Warter
Journal:  Neurology       Date:  2003-03-11       Impact factor: 9.910

Review 3.  New autosomal recessive cerebellar ataxias with oculomotor apraxia.

Authors:  Isabelle Le Ber; Alexis Brice; Alexandra Dürr
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 4.  Clinical features and molecular genetics of autosomal recessive cerebellar ataxias.

Authors:  Brent L Fogel; Susan Perlman
Journal:  Lancet Neurol       Date:  2007-03       Impact factor: 44.182

Review 5.  Pathways to motor incoordination: the inherited ataxias.

Authors:  Franco Taroni; Stefano DiDonato
Journal:  Nat Rev Neurosci       Date:  2004-08       Impact factor: 34.870

6.  Aprataxin, poly-ADP ribose polymerase 1 (PARP-1) and apurinic endonuclease 1 (APE1) function together to protect the genome against oxidative damage.

Authors:  Janelle L Harris; Burkhard Jakob; Gisela Taucher-Scholz; Grigory L Dianov; Olivier J Becherel; Martin F Lavin
Journal:  Hum Mol Genet       Date:  2009-07-30       Impact factor: 6.150

7.  Severe generalized dystonia as a presentation of a patient with aprataxin gene mutation.

Authors:  Yoshiki Sekijima; Takao Hashimoto; Osam Onodera; Hidetoshi Date; Tomomi Okano; Kosuke Naito; Shoji Tsuji; Shu-ichi Ikeda
Journal:  Mov Disord       Date:  2003-10       Impact factor: 10.338

8.  Ataxia with oculomotor apraxia type 1 in Southern Italy: late onset and variable phenotype.

Authors:  C Criscuolo; P Mancini; F Saccà; G De Michele; A Monticelli; L Santoro; V Scarano; S Banfi; A Filla
Journal:  Neurology       Date:  2004-12-14       Impact factor: 9.910

9.  A novel mutation of aprataxin associated with ataxia ocular apraxia type 1: phenotypical and genotypical characterization.

Authors:  Moreno Ferrarini; Giovanna Squintani; Tiziana Cavallaro; Sergio Ferrari; Nicolo' Rizzuto; Gian Maria Fabrizi
Journal:  J Neurol Sci       Date:  2007-06-18       Impact factor: 3.181

10.  Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients.

Authors:  F Taroni; E Verderio; F Dworzak; P J Willems; P Cavadini; S DiDonato
Journal:  Nat Genet       Date:  1993-07       Impact factor: 38.330

View more
  24 in total

Review 1.  Molecular underpinnings of Aprataxin RNA/DNA deadenylase function and dysfunction in neurological disease.

Authors:  Matthew J Schellenberg; Percy P Tumbale; R Scott Williams
Journal:  Prog Biophys Mol Biol       Date:  2015-01-29       Impact factor: 3.667

2.  Lack of aprataxin impairs mitochondrial functions via downregulation of the APE1/NRF1/NRF2 pathway.

Authors:  Beatriz Garcia-Diaz; Emanuele Barca; Andrea Balreira; Luis C Lopez; Saba Tadesse; Sindhu Krishna; Ali Naini; Caterina Mariotti; Barbara Castellotti; Catarina M Quinzii
Journal:  Hum Mol Genet       Date:  2015-05-14       Impact factor: 6.150

3.  Clinical presentations of coenzyme q10 deficiency syndrome.

Authors:  Catarina M Quinzii; Valentina Emmanuele; Michio Hirano
Journal:  Mol Syndromol       Date:  2014-07

4.  Cerebellar Ataxia and CoQ10 Deficiency.

Authors:  Catarina M Quinzii; Michio Hirano; Ali Naini
Journal:  J Neurol Disord Stroke       Date:  2013

Review 5.  Neurological disorders associated with DNA strand-break processing enzymes.

Authors:  Bingcheng Jiang; J N Mark Glover; Michael Weinfeld
Journal:  Mech Ageing Dev       Date:  2016-07-25       Impact factor: 5.432

6.  Clinical, Biomarker, and Molecular Delineations and Genotype-Phenotype Correlations of Ataxia With Oculomotor Apraxia Type 1.

Authors:  Mathilde Renaud; Maria-Céu Moreira; Bondo Ben Monga; Diana Rodriguez; Rabab Debs; Perrine Charles; Malika Chaouch; Farida Ferrat; Chloé Laurencin; Laurent Vercueil; Martial Mallaret; Abderrahim M'Zahem; Lamia Ali Pacha; Meriem Tazir; Caroline Tilikete; Elisabeth Ollagnon; François Ochsner; Thierry Kuntzer; Hans H Jung; Jean-Marie Beis; Jean-Claude Netter; Atbin Djamshidian; Mattew Bower; Armand Bottani; Richard Walsh; Sinead Murphy; Thomas Reiley; Éric Bieth; Filip Roelens; Bwee Tien Poll-The; Charles Marques Lourenço; Laura Bannach Jardim; Rachel Straussberg; Pierre Landrieu; Emmanuel Roze; Stéphane Thobois; Jean Pouget; Claire Guissart; Cyril Goizet; Alexandra Dürr; Christine Tranchant; Michel Koenig; Mathieu Anheim
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

Review 7.  Heterogeneity of coenzyme Q10 deficiency: patient study and literature review.

Authors:  Valentina Emmanuele; Luis C López; Luis López; Andres Berardo; Ali Naini; Saba Tadesse; Bing Wen; Erin D'Agostino; Martha Solomon; Salvatore DiMauro; Catarina Quinzii; Michio Hirano
Journal:  Arch Neurol       Date:  2012-08

Review 8.  Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: Is damage response signaling a potential therapeutic target?

Authors:  Haibo Wang; Prakash Dharmalingam; Velmarini Vasquez; Joy Mitra; Istvan Boldogh; K S Rao; Thomas A Kent; Sankar Mitra; Muralidhar L Hegde
Journal:  Mech Ageing Dev       Date:  2016-09-20       Impact factor: 5.432

9.  Childhood-onset autosomal recessive ataxias: a cross-sectional study from Turkey.

Authors:  Hatice Mutlu-Albayrak; Emre Kırat; Gürkan Gürbüz
Journal:  Neurogenetics       Date:  2019-11-19       Impact factor: 2.660

Review 10.  Primary coenzyme Q10 (CoQ 10) deficiencies and related nephropathies.

Authors:  Fatih Ozaltin
Journal:  Pediatr Nephrol       Date:  2013-06-05       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.